---
id: out-diabetes-briefing-20260421-round1-working-en
type: output
output_kind: briefing
language: en
topic: diabetes
question: "Based on the current feline diabetes seed corpus, what is the first usable internal view across pathogenesis, remission, diet/obesity, comorbidity, treatment, monitoring, and SGLT2 regulatory boundaries?"
source_ids: [src-diabetes-001, src-diabetes-005, src-diabetes-006, src-diabetes-007, src-diabetes-009, src-diabetes-010, src-diabetes-011, src-diabetes-012, src-diabetes-013, src-diabetes-014, src-diabetes-015, src-diabetes-020, src-diabetes-022, src-diabetes-024, src-reg-010, src-reg-011, src-reg-012, src-reg-013]
generated_at: 2026-04-21
verification_status: compiled
decision_grade: no
language_qa_status: light_checked
language_qa_notes: "2026-04-24 checked for verification-state sync; working-English layer only, not decision-grade clinical guidance."
owner: codex
status: draft
evidence_policy:
  quoted_fact: []
  source_supported_conclusion: []
  llm_inference: []
---

# Internal Briefing: Feline Diabetes Round 1

## User Question

Based on the current feline diabetes seed corpus, what is the first usable internal view across pathogenesis, remission, diet/obesity, comorbidity, treatment, monitoring, and SGLT2 regulatory boundaries?

## Executive Answer

Feline diabetes should currently be modeled as a `reversible-potential metabolic disease with chronic endocrine and comorbidity constraints`.

That framing is important because the literature can otherwise collapse into two bad simplifications:

- a remission-protocol story where every treatment branch is judged by whether it produces remission
- a drug-frontier story where newer SGLT2 products outrun candidate-selection, safety, and label boundaries

The current 24-source paper corpus and four U.S. SGLT2 regulatory/label cards support a more useful first architecture:

- type-2-like metabolic pathogenesis is central, but not universal
- obesity and body condition shape mechanism, recognition, and treatment sequencing
- remission is real, but predictor and protocol certainty remain limited
- endocrine-secondary disease, pancreatitis, and neuropathy must stay visible
- diet, insulin, SGLT2, alpha-glucosidase, incretin/frontier, and remission-control branches are not interchangeable
- U.S. SGLT2 label control is now source-backed, but it is not global approval status or comparative superiority evidence

This file is the working-English briefing. Derived English and Chinese outputs should stay lighter than this layer and should not imply stronger evidence than the current compiled source set supports.

## Evidence-Backed Points

### quoted_fact

- The diabetes source set includes broad pathogenesis reviews, diet-management papers, remission evidence, epidemiology, endocrine comorbidity, pancreatitis, neuropathy, SGLT2 treatment, insulin glargine U300, and U.S. SGLT2 FDA/label sources.
- Diet evidence spans prevention/management review material, low-carbohydrate versus high-fiber framing, low-carbohydrate/low-fiber study context, and high-protein diet context.
- U.S. SGLT2 source control now includes Bexacat and Senvelgo FDA FOI cards plus current-label cards.

### source_supported_conclusion

- The lead disease frame should be mixed metabolic/endocrine disease, not one universal type-2 template.
- Remission should be treated as a real outcome branch, not as the sole organizing principle for treatment.
- The remission systematic-review branch is already strong enough to keep remission visible, but the current module preserves evidence-quality limits and blocks one-factor prediction.
- Obesity/body-condition logic belongs in both mechanism and translation because stabilization, diet composition, glycemic control, and weight loss are sequencing questions.
- SGLT2 inhibitors are a real treatment/regulatory branch for selected cats, but current-label warnings, contraindications, ketone monitoring, and insulin-naive boundaries must govern interpretation.
- Treatment should be organized by role and safety boundary before any flat ranking.
- Regulatory claims should stay jurisdiction-specific; U.S. FDA and DailyMed cards do not answer EMA, UK, China, or global status.

### llm_inference

- The most reusable first-wave Diabetes architecture is:
  1. mixed pathogenesis and comorbidity frame
  2. remission boundary
  3. diet/obesity sequencing
  4. treatment branch separation
  5. diagnostic/monitoring gates
  6. SGLT2 label and regulatory boundary
- Diabetes is now a good fifth-module test of whether the vault can handle an active product-label branch without turning it into clinical product recommendation.

## Uncertainty / Limits

- All 24 paper cards are now `verification_status: deep_extracted`, but stronger topic/output-level compression is still needed before protocol ranking.
- Full-text clinical review is still needed before strong protocol ranking.
- The current output does not rank insulin families, SGLT2 products, or diet protocols.
- Non-U.S. SGLT2 regulatory status has not been checked.
- This briefing is not veterinary medical advice, a prescribing protocol, or a decision-grade guideline.

## Suggested Write-Back Targets

- `topics/diabetes/current-state-dashboard.md`
- `topics/diabetes/synthesis-index.md`
- `topics/diabetes/translation-brief.md`
- `topics/diabetes/regulatory-brief.md`
- `system/indexes/diabetes-output-language-matrix.md`
- `system/indexes/source-processing-ledger-120-20260421.md`

## Promotion Judgment

- repeated? `yes`
- structurally clarifying? `yes`
- evidence-safe enough for this layer? `partly`
- smallest durable home: `output layer + dashboard/output-matrix state sync`

### Reason

The Diabetes module now repeatedly needs a compressed answer that separates remission, diet/obesity, comorbidity, treatment, monitoring, and SGLT2 label control. A first output layer is justified, but stronger clinical ranking remains held.

### Decision

Promote the first Diabetes output set; hold full-text clinical ranking, product superiority language, and non-U.S. regulatory claims.
